ADMET
July 9 - 10, 2018 - London UKSMi Group
ssapal@smi-online.co.uk
Phone:02078276000
Chaired by Eric Bloome, Vice President, Global Pre-Clinical Safety Senior Research Fellow, AbbVie Developments in ADMET and novel technologies determine the properties of a drug candidate in the preclinical stage of drug discovery. Poor ADMET properties are the principal cause for a candidate to fail at any stage of drug development. ADME-Toxicology and Pharmacokinetic studies are the key strategic check-points for pharmaceutical companies to reduce drug discovery cost, and minimise production times. The growing use of ADMET technologies is driving the market growth, which is estimated to reach $14,319.9 Million by 2022, with a CAGR of 10.6% from 2016 to 2022*. The main objective of early prediction of ADME properties of a compound is to increase the success rate of it reaching the development stage. *Source: http://bit.ly/2hMJcgU Join our expert speaker panels at the ADMET conference to ensure you do not miss out on the latest developments! Presenting new technologies, specific case studies and PK modelling strategies in the areas of DMPK, PBPK, PKPD, in vitro / ex vivo / in vivo / in silico, biologics, transporters, hazard and safety assessments, ADMET modelling, and many more. This event is CPD accredited. The ADMET conference will cover new developments in all areas of the ADMET sector, from the evaluation of novel PBPK modelling techniques to the validation of humanised mice models. Join us this year in July to hear from our expert speaker panel, bringing you interesting case studies and detailed presentations on new and industry relevant topics, including: ADME/PK Optimisation for Drug Design and Discovery Physiochemical Assessments Drug Screening Technology In Vitro to Human In Vivo Translation DMPK, PBPK and PKPD Modelling Pre-/Clinical Toxicity Biopharmaceuticals Accurate First-in-Human Dose Predictions Transporters, Bioavailability, Formulation Metabolism Studies Drug-Drug Interactions